Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 18 04:00PM ET
0.8318
Dollar change
+0.0028
Percentage change
0.34
%
Index- P/E- EPS (ttm)-352.42 Insider Own0.80% Shs Outstand5.46M Perf Week-10.56%
Market Cap4.54M Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float5.42M Perf Month-35.52%
Income-15.61M PEG- EPS next Q-0.80 Inst Own0.74% Short Float3.36% Perf Quarter-78.17%
Sales0.00M P/S- EPS this Y41.95% Inst Trans-2.87% Short Ratio0.11 Perf Half Y-83.83%
Book/sh3.73 P/B0.22 EPS next Y93.88% ROA-202.65% Short Interest0.18M Perf Year-99.40%
Cash/sh2.39 P/C0.35 EPS next 5Y67.95% ROE-477.53% 52W Range0.77 - 200.00 Perf YTD-86.18%
Dividend Est.- P/FCF- EPS past 5Y70.59% ROIC-142.34% 52W High-99.58% Beta0.78
Dividend TTM- Quick Ratio4.93 Sales past 5Y- Gross Margin- 52W Low7.81% ATR (14)0.11
Dividend Ex-Date- Current Ratio4.93 EPS Y/Y TTM95.95% Oper. Margin- RSI (14)32.65 Volatility5.44% 3.69%
Employees5 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price16.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q99.84% Payout- Rel Volume0.08 Prev Close0.83
Sales Surprise- EPS Surprise21.00% Sales Q/Q- EarningsMay 15 AMC Avg Volume1.71M Price0.83
SMA20-16.50% SMA50-21.73% SMA200-80.13% Trades Volume145,042 Change0.34%
Date Action Analyst Rating Change Price Target Change
Dec-28-20Downgrade Ladenburg Thalmann Buy → Neutral
Aug-24-20Initiated Ladenburg Thalmann Buy $11
Jun-05-25 08:05AM
May-16-25 08:05AM
May-13-25 09:35AM
07:00AM
Apr-02-25 08:46AM
08:00AM Loading…
Mar-25-25 08:00AM
Feb-26-25 09:05AM
Feb-20-25 09:00AM
Feb-19-25 09:00AM
08:30AM
Feb-18-25 09:00AM
Feb-10-25 08:00AM
Dec-05-24 09:10AM
09:10AM
Nov-25-24 09:00AM
08:55AM Loading…
Nov-18-24 08:55AM
Nov-15-24 09:10AM
Nov-04-24 09:15AM
Nov-01-24 09:00AM
Oct-23-24 02:50PM
Oct-10-24 09:00AM
Oct-08-24 09:15AM
Sep-23-24 09:00AM
Sep-12-24 09:00AM
Sep-04-24 09:05AM
Sep-03-24 08:00AM
Aug-27-24 09:10AM
Aug-22-24 09:15AM
Aug-15-24 08:00AM
Jul-30-24 07:00AM
09:05AM Loading…
Jul-25-24 09:05AM
Jul-16-24 09:15AM
Jul-11-24 07:29AM
Jul-03-24 11:10AM
Jun-26-24 08:00AM
Jun-14-24 03:11PM
Jun-10-24 08:00AM
Jun-03-24 08:05AM
May-20-24 08:30AM
May-16-24 11:53AM
07:45AM
Apr-23-24 09:00AM
Apr-22-24 10:15AM
Apr-01-24 11:52PM
05:00PM
09:05AM
Jan-29-24 09:00PM
Jan-18-24 08:45AM
Jan-17-24 08:45AM
Dec-18-23 08:35AM
Dec-06-23 09:00AM
Nov-22-23 09:05AM
Nov-16-23 10:00AM
Nov-15-23 08:00AM
Oct-19-23 09:05AM
Oct-18-23 10:00AM
Oct-16-23 09:00AM
Oct-11-23 08:45AM
Sep-07-23 08:45AM
Sep-05-23 08:45AM
Aug-14-23 08:35AM
07:35AM
Aug-03-23 08:15AM
08:00AM
Jul-27-23 09:05AM
Jul-05-23 08:45AM
Jun-14-23 09:05AM
May-25-23 09:05AM
May-15-23 08:35AM
May-08-23 08:45AM
May-03-23 08:45AM
Apr-27-23 08:45AM
Apr-17-23 06:54AM
Apr-10-23 08:45AM
Apr-06-23 09:05AM
Apr-03-23 08:05AM
Mar-29-23 09:05AM
Mar-13-23 07:05AM
Mar-09-23 09:05AM
Feb-07-23 08:45AM
Jan-12-23 08:45AM
Jan-11-23 01:00PM
Jan-05-23 09:05AM
Jan-03-23 02:28PM
12:00PM
Dec-08-22 09:08AM
Dec-05-22 08:05AM
Nov-30-22 10:00PM
Nov-28-22 04:53PM
Nov-15-22 01:09PM
Nov-14-22 04:05PM
Nov-02-22 08:45AM
Oct-10-22 09:00AM
Oct-07-22 08:00AM
Sep-28-22 09:05AM
Sep-23-22 09:00AM
Sep-07-22 08:45AM
Aug-15-22 08:05AM
Jul-25-22 08:05AM
Jun-23-22 08:35AM
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.